Bronchial biopsy specimen as a surrogate for DNA methylation analysis in inoperable lung cancer

Global cancer statistics, 2012

(2015) Lindsey A. Torre et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Phase I/II study of gefitinib (Iressa®) and vorinostat (IVORI) in previously treated patients with advanced non-small cell lung cancer

(2015) Ji-Youn Han et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Homeobox A9 directly targeted by miR-196b regulates aggressiveness through nuclear Factor-kappa B activity in non-small cell lung cancer cells

(2015) Seong-Lan Yu et al.   MOLECULAR CARCINOGENESIS

Epigenetics of lung cancer

(2015) Scott M. Langevin et al.   Translational Research

The SOX17/miR-371-5p/SOX2 axis inhibits EMT, stem cell properties and metastasis in colorectal cancer

(2015) Yuling Li et al.   Oncotarget

Alterations of immune response of non-small cell lung cancer with Azacytidine

(2015) John Wrangle et al.   Oncotarget

HBP1 promoter methylation augments the oncogenic β-catenin to correlate with prognosis in NSCLC

(2014) Ruo-Chia Tseng et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Phase I/II trial of vorinostat (SAHA) and erlotinib for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations after erlotinib progression

(2014) Noemi Reguart et al.   LUNG CANCER

HOXA9inhibits migration of lung cancer cells and its hypermethylation is associated with recurrence in non-small cell lung cancer

(2014) Jung-Ah Hwang et al.   MOLECULAR CARCINOGENESIS

A data-driven approach to preprocessing Illumina 450K methylation array data

(2013) Ruth Pidsley et al.   BMC GENOMICS

Molecular sputum analysis for the diagnosis of lung cancer

(2013) A J Hubers et al.   BRITISH JOURNAL OF CANCER

Low SOX17 expression is a prognostic factor and drives transcriptional dysregulation and esophageal cancer progression

(2013) I-Ying Kuo et al.   INTERNATIONAL JOURNAL OF CANCER

Vorinostat and bortezomib as third-line therapy in patients with advanced non-small cell lung cancer: a Wisconsin Oncology Network Phase II study

(2013) Tien Hoang et al.   INVESTIGATIONAL NEW DRUGS

A Prospective PCR-Based Screening for the EML4-ALK Oncogene in Non-Small Cell Lung Cancer

(2012) M. Soda et al.   CLINICAL CANCER RESEARCH

Randomized Phase II Trial of Erlotinib With and Without Entinostat in Patients With Advanced Non–Small-Cell Lung Cancer Who Progressed on Prior Chemotherapy

(2012) Samir E. Witta et al.   JOURNAL OF CLINICAL ONCOLOGY

Genome-wide combination profiling of DNA copy number and methylation for deciphering biomarkers in non-small cell lung cancer patients

(2011) Ji Woong Son et al.   CANCER LETTERS

Phase 1 clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung cancer based on in vitro assessments of the combination

(2011) Michael Millward et al.   INVESTIGATIONAL NEW DRUGS

Combination Epigenetic Therapy Has Efficacy in Patients with Refractory Advanced Non-Small Cell Lung Cancer

(2011) R. A. Juergens et al.   Cancer Discovery

Quantitative Analysis of Tumor in Bronchial Biopsy Specimens

(2010) Caroline L. Coghlin et al.   Journal of Thoracic Oncology

Sox17, the canonical Wnt antagonist, is epigenetically inactivated by promoter methylation in human breast cancer

(2009) De-Yuan Fu et al.   BREAST CANCER RESEARCH AND TREATMENT

Carboplatin and Paclitaxel in Combination With Either Vorinostat or Placebo for First-Line Therapy of Advanced Non–Small-Cell Lung Cancer

(2009) Suresh S. Ramalingam et al.   JOURNAL OF CLINICAL ONCOLOGY